Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
The U.S. government continues to create a lot of uncertainty for the medical device industry, but medtech companies are still making some big moves.
The frenzy of major mergers continues, which makes sense from an investor standpoint when it comes to reducing risk. Meanwhile, companies from outside the industry – including such high-tech giants as Apple, Google and Microsoft – see medical as a great way to diversify and hedge bets. Read more
Kevin Sayer describes Dexcom‘s history as punctuated by “firsts” – its continuous glucose meter was the first to connect to a phone. Last year, the company’s tool became the first to be approved by the FDA as one from which a patient with diabetes can make insulin dosing decisions.
When Sayer took the helm as president & CEO of Dexcom in 2011, he was no stranger to the diabetes space. He served as the CFO of MiniMed from 1994 until it was bought by Medtronic in 2001, at which point he joined the medtech giant’s diabetes business. Read more
3. India’s NPPA tells Boston Scientific to choose between exiting stent market or seeking higher price caps
India’s National Pharmaceutical Pricing Authority has told Boston Scientific it has to choose between either seeking to withdraw its premium coronary stents from the market or seeking a higher price for them after the Authority received applications for both options, according to an Indian Economic Times report.
The company was blocked from removing its Promus Premier and Synergy stents from the country earlier this year after seeking permission to do so, according to the report, and has again approached the NPPA seeking permission to exit the market. Read more
Becton Dickinson has offered concessions to address certain EU antitrust concerns as it looks to acquire C.R. Bard in a $24 billion deal, according to the European Commission.
Franklin Lakes, N.J.-based Becton Dickinson submitted the concessions yesterday, according to a filing on the EU competition authority, but did not provide any details on the submission. Read more
Medtronic said today it won expanded FDA approval for its HeartWare HVAD system, now cleared as a destination therapy for patients with advanced heart failure who are not candidates for heart transplants.
The HeartWare HVAD system is a left ventricular assist device designed to aid the heart and increase the amount of blood pumped through the body, the Fridley, Minn.-based company said. Read more